Table 1. Baseline characteristics of the study population with raltegravir and dolutegravir containing antiretroviral regimen (n = 4041) and reasons for treatment modification.

	Raltegravir N = 2091		Dolutegravir N = 1950
	n	%	n	%	P value
Male	1474	70.5	1455	74.6	0.003
Age, median (IQR)	48	41–54	48	40–54	0.447
White ethnicity	1752	83.8	1566	80.3	0.004
Risk
MSM	887	42.4	997	51.1
Heterosexual	723	34.6	679	34.8	<0.001
PWID	245	11.7	107	5.5
Other	236	11.3	167	8.6
Prior AIDS-defining condition	623	29.8	381	19.5	<0.001
HCV coinfection	641	30.7	377	19.3	0.001
CD4+ cells per μl
<350	713	34.1	341	17.5	<0.001
350–500	481	23.0	421	21.6
>500	897	42.9	1188	60.9
HIV RNA >100 000 copies per ml	574	42.8	608	39.4	0.069
Treatment-naive	188	9.0	327	16.8	<0.001
Backbone
Abacavir–lamivudine	302	14.5	1149	59.1	<0.001
Tenofovir–emtricitabine	955	45.7	586	30.1
Other	833	39.9	209	10.8
Treatment modification	364	17.4	204	10.5	<0.0001
Treatment failure	10	0.48	2	0.10	0.028
Toxicity
Total	106	5.07	75	3.85	0.060
Gastrointestinal	6	0.29	19	0.97	0.005
Liver	2	0.10	7	0.36	0.098
Lipids	12	0.57	1	0.05	0.003
Neuropsychiatric	13	0.62	33	1.69	0.001
Kidney	3	0.14	0	0.00	0.251
Hematologic	9	0.43	2	0.10	0.046
Allergy	16	0.77	4	0.21	0.011
IRIS	6	0.29	1	0.05	0.076
Other	39	1.87	8	0.41	<0.0001
Convenience
Total	210	10.04	92	4.72	<0.0001
Patient's wish	54	2.58	44	2.26	0.502
Physician's decision	94	4.50	26	1.33	<0.0001
Treatment simplification	62	2.97	22	1.13	<0.0001
Pregnancy	3	0.14	11	0.56	0.023
Other	25	2.97	18	1.13	0.399
No information	10	0.48	6	0.31	0.390

IQR, interquartile range; IRIS, immune reconstitution inflammatory syndrome; PWID, people who inject drugs.